Taiho Pharmaceutical Report issue

For profit Phase 2
Founded: Tokyo Japan (1993)
Status: Acquired by Otsuka (1993)

Organization Overview

First Clinical Trial
2019
NCT04076761
First Marketed Drug
2015
tipiracil (lonsurf)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Taiho Oncology | TAIHO ONCOLOGY | Taiho Pharma Canada, Inc.

Active Ingredients

Marketed Drugs (3)

futibatinib (Lytgobi) (2022)

tipiracil (lonsurf) (2015)

trifluridine (viroptic) (2015)

Drugs in Phase 2 Trials (2)

tipiracil (lonsurf) (1 trial)

trifluridine (viroptic) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Bile Duct Neoplasms (Phase 2)

Cholangiocarcinoma (Phase 2)

Rectal Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2